Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Posted as supplied by the authors
Creating a Propensity Score
The creation of a propensity score is based on a logistic regression with the dependent variable taking on the value of "1" if the individual is in the intervention group and "0" if the individual is in the comparison group, and with the potential confounders as the independent variables. The logistic regression is used to estimate the probability that, based on that individual’s potential confounders, that individual would be in the intervention or comparison group. Using the estimated coefficients from the logistic regression model and the measured potential confounders for an individual it is possible to calculate an estimated probability of being in the intervention group for each individual in the study. This estimated probability is called the propensity score for that individual.
The logistic regression determines the extent to which the potential confounders can predict whether an individual is in one group or the other, and provides an indication of the degree to which the groups are unbalanced on these confounders. The C-statistic from logistic regression provides a summary of the accuracy of the overall prediction based on the model and the coefficients for each of the independent variables provides an estimate of the effect of their independent effects.
Tables 1 and 2 contain the results of logistic regressions for Comparisons 1 and 2. For Comparison 1, a logistic regression model that contains no interaction results in a C-statistic of 0.875 indicating that the model can readily discriminate whether an individual is in the intervention or comparison group based on the potential confounders. This provides clear evidence that the groups are quite different in terms of these characteristics. The estimated odds ratio for the diagnosis of dementia is almost 18 indicating that this characteristic, even when one controls for other factors such as age and sex, is much more common in the intervention group than the comparison group. For Comparison 2, even a logistic regression with extensive interaction terms has a C-Statistic of 0.565 indicating that in this study the confounders are not very useful at discriminating between individuals with dementia who received atypical antipsyhcotics and those who received typical antipsyhoctics.
Propensity scores can be included as covariates in regression analyses, be used to define matches, or can be used to create strata. For the purposes of an example, the propensity scores were used to create strata. The results of the analysis of the association between hip fracture and atypical antipsychotic use within each of these strata are provided in a separate document.
|
Table 1: Logistic regression for creation of propensity score |
||||||
|
Comparison 1: Atypical users to non-users |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect |
Odds Ratio Estimate |
Lower 95% CL |
Upper 95% CL |
Parameter Estimate |
Standard Error |
c statistic |
|
Age, yrs |
1.13 |
1.127 |
1.134 |
0.1227 |
0.00142 |
0.875 |
|
Age squared |
0.992 |
0.992 |
0.992 |
-0.00804 |
0.000113 |
|
|
Male |
1.082 |
1.054 |
1.111 |
0.0791 |
0.0135 |
|
|
Long acting benzodiazapine |
1.505 |
1.406 |
1.611 |
0.4087 |
0.0347 |
|
|
Short acting benzodiazapine |
3.691 |
3.599 |
3.786 |
1.306 |
0.0129 |
|
|
bisphosphonates |
1.492 |
1.411 |
1.578 |
0.4 |
0.0285 |
|
|
oestrogen |
1.022 |
0.968 |
1.079 |
0.0217 |
0.0277 |
|
|
alcoholism |
2.039 |
1.921 |
2.164 |
0.7124 |
0.0305 |
|
|
Chronic Lung Disease (COPD) |
1.063 |
1.033 |
1.093 |
0.0608 |
0.0145 |
|
|
Falls |
1.286 |
1.228 |
1.347 |
0.2519 |
0.0235 |
|
|
Hyperparathyroidism |
1.54 |
1.073 |
2.21 |
0.4319 |
0.1844 |
|
|
Hyperthyroidism |
1.71 |
1.396 |
2.095 |
0.5365 |
0.1036 |
|
|
Obesity |
0.905 |
0.843 |
0.971 |
-0.0998 |
0.036 |
|
|
Osteoporosis |
1.031 |
0.984 |
1.08 |
0.0306 |
0.0236 |
|
|
Parkinsonism |
2.554 |
2.44 |
2.674 |
0.9377 |
0.0233 |
|
|
Chronic renal failure |
1.219 |
1.162 |
1.278 |
0.1977 |
0.0242 |
|
|
rheumatoid arthritis |
0.88 |
0.833 |
0.93 |
-0.1278 |
0.0282 |
|
|
stroke |
1.359 |
1.306 |
1.415 |
0.3071 |
0.0205 |
|
|
visual impairment |
1.245 |
1.149 |
1.347 |
0.2188 |
0.0405 |
|
|
dementia |
17.927 |
17.463 |
18.404 |
2.8863 |
0.0134 |
|
|
|
|
|
|
|
|
|
|
Table 2: Logistic regression for creation of Propensity Score |
||||||
|
Comparison 2: Atypical vs. Typical neuroleptics restricted to individuals with dementia |
|
|
|
|
||
|
|
|
|
|
|
|
|
|
Effect |
Parameter Estimate |
Standard Error |
Odds Ratio Estimate |
Lower 95% CL |
Upper 95% CL |
c statistic |
|
Age, yrs |
-0.00274 |
0.00256 |
0.997 |
0.992 |
1.002 |
0.565 |
|
Age squared (age2) |
-0.00131 |
0.000258 |
0.999 |
0.998 |
0.999 |
|
|
Male |
0.8128 |
0.2389 |
2.254 |
1.411 |
3.6 |
|
|
Long acting benzodiazepine (LAB) |
-0.5486 |
0.6065 |
0.578 |
0.176 |
1.897 |
|
|
Short acting benzodiazepine (SAB) |
-0.5528 |
0.2215 |
0.575 |
0.373 |
0.888 |
|
|
bisphosphonate |
0.6685 |
0.6717 |
1.951 |
0.523 |
7.278 |
|
|
oestrogen |
1.6924 |
0.5576 |
5.433 |
1.821 |
16.205 |
|
|
alcoholism |
-0.2528 |
0.4497 |
0.777 |
0.322 |
1.875 |
|
|
Chronic Lung Disease (COPD) |
-0.4181 |
0.2573 |
0.658 |
0.398 |
1.09 |
|
|
Falls |
-0.0866 |
0.3803 |
0.917 |
0.435 |
1.932 |
|
|
Obesity |
0.0908 |
0.6722 |
1.095 |
0.293 |
4.089 |
|
|
Osteoporosis |
0.0925 |
0.4567 |
1.097 |
0.448 |
2.685 |
|
|
Parkinsonism |
0.5631 |
0.3663 |
1.756 |
0.857 |
3.6 |
|
|
Chronic renal failure (CRF) |
-0.8932 |
0.4225 |
0.409 |
0.179 |
0.937 |
|
|
rheumatoid arthritis |
0.2148 |
0.5273 |
1.24 |
0.441 |
3.485 |
|
|
stroke |
-0.1779 |
0.3334 |
0.837 |
0.435 |
1.609 |
|
|
Visual impairment |
-2.9099 |
0.8644 |
0.054 |
0.01 |
0.297 |
|
|
Interaction age male |
-0.0104 |
0.00295 |
0.99 |
0.984 |
0.995 |
|
|
interaction age LAB |
0.00304 |
0.00748 |
1.003 |
0.988 |
1.018 |
|
|
Interaction age SAB |
0.00629 |
0.00273 |
1.006 |
1.001 |
1.012 |
|
|
Interaction age bisphosphonate |
0.00785 |
0.00833 |
1.008 |
0.992 |
1.024 |
|
|
Interaction age oestrogen |
-0.0166 |
0.00696 |
0.984 |
0.97 |
0.997 |
|
|
Interaction age alcoholism |
0.00174 |
0.00549 |
1.002 |
0.991 |
1.013 |
|
|
Interaction age COPD |
0.00622 |
0.00316 |
1.006 |
1 |
1.013 |
|
|
Interaction age falls |
0.000248 |
0.00467 |
1 |
0.991 |
1.009 |
|
|
Interaction age obesity |
-0.00469 |
0.00829 |
0.995 |
0.979 |
1.012 |
|
|
Interaction age osteoporosis |
0.000791 |
0.00565 |
1.001 |
0.99 |
1.012 |
|
|
Interaction age Parkinsonism |
-0.00778 |
0.00451 |
0.992 |
0.984 |
1.001 |
|
|
Interaction age CRF |
0.0122 |
0.00518 |
1.012 |
1.002 |
1.023 |
|
|
Interaction age rheumatoid arthritis |
-0.00524 |
0.00652 |
0.995 |
0.982 |
1.008 |
|
|
Interaction age stroke |
0.00182 |
0.00407 |
1.002 |
0.994 |
1.01 |
|
|
Interaction age visual impairment |
0.0357 |
0.0105 |
1.036 |
1.015 |
1.058 |
|
|
Interaction male age2 |
0.00128 |
0.000318 |
1.001 |
1.001 |
1.002 |
|
|
Interaction male LAB |
-0.1816 |
0.1116 |
0.834 |
0.67 |
1.038 |
|
|
Interaction male SAB |
-0.0331 |
0.0376 |
0.967 |
0.899 |
1.041 |
|
|
Interaction male bisphosphonate |
-0.0421 |
0.1593 |
0.959 |
0.702 |
1.31 |
|
|
Interaction male alcoholism |
-0.0466 |
0.0752 |
0.954 |
0.824 |
1.106 |
|
|
Interaction male COPD |
-0.1126 |
0.043 |
0.893 |
0.821 |
0.972 |
|
|
Interaction male falls |
0.0991 |
0.0607 |
1.104 |
0.98 |
1.244 |
|
|
Interaction male obesity |
0.0854 |
0.1227 |
1.089 |
0.856 |
1.385 |
|
|
Interaction male osteoporosis |
0.0344 |
0.0937 |
1.035 |
0.861 |
1.243 |
|
|
Interaction male Parkinsonism |
0.1239 |
0.0612 |
1.132 |
1.004 |
1.276 |
|
|
Interaction male CRF |
-0.024 |
0.0682 |
0.976 |
0.854 |
1.116 |
|
|
Interaction male rheumatoid arthritis |
0.0561 |
0.0904 |
1.058 |
0.886 |
1.263 |
|
|
Interaction male stroke |
-0.0648 |
0.0538 |
0.937 |
0.844 |
1.041 |
|
|
Interaction male visual impairment |
-0.0801 |
0.1134 |
0.923 |
0.739 |
1.153 |
|
|
Interaction age2 LAB |
0.000111 |
0.000879 |
1 |
0.998 |
1.002 |
|
|
Interaction age2 SAB |
0.000288 |
0.000288 |
1 |
1 |
1.001 |
|
|
Interaction age2 bisphosphonates |
-0.00066 |
0.000907 |
0.999 |
0.998 |
1.001 |
|
|
Interaction age2 oestrogen |
0.000726 |
0.000806 |
1.001 |
0.999 |
1.002 |
|
|
Interaction age2 alcoholism |
0.00079 |
0.000631 |
1.001 |
1 |
1.002 |
|
|
Interaction age2 COPD |
-0.00036 |
0.000341 |
1 |
0.999 |
1 |
|
|
Interaction age2 falls |
-0.00027 |
0.000456 |
1 |
0.999 |
1.001 |
|
|
Interaction age2 obesity |
0.000829 |
0.000977 |
1.001 |
0.999 |
1.003 |
|
|
Interaction age2 osteoporosis |
-0.00011 |
0.000585 |
1 |
0.999 |
1.001 |
|
|
Interaction age2 Parkinsonism |
9.14E-06 |
0.000539 |
1 |
0.999 |
1.001 |
|
|
Interaction age2 CRF |
-0.00085 |
0.000562 |
0.999 |
0.998 |
1 |
|
|
Interaction age2 rheumatoid arthritis |
0.000359 |
0.000703 |
1 |
0.999 |
1.002 |
|
|
Interaction age2 stroke |
-0.00006 |
0.000448 |
1 |
0.999 |
1.001 |
|
|
Interaction age2_visual impairment |
-0.00121 |
0.000892 |
0.999 |
0.997 |
1.001 |
|